EUCTR2006-006233-40-DE进行中（未招募）1 期
Ranibizumab in idiopathic macular telangiectasia, type2 A prospective interventional non-randomized study comparing the efficacy and safety of intravitreal ranibizumab (dosing regimen 0.5mg every month over a period of one year) in type 2 idiopathic macular telangiectasia[Intravitreales Ranibizumab zur Therapie von idiopathischen makulären Teleangiektasien, Typ 2]
Department of Ophthalmology, Bonn University0 个研究点目标入组 10 人开始时间: 2007年3月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age >18 years
- •Written Informed Consent has been obtained.
- •Best corrected visual acuity in the study eye: 20/200 - 20/32.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with other retinal vascular diseases. such as Diabetic Retinopathy or retinal vascular occlusion
- •Previous intravitreal Injection of antiangiogenetic drugs into the study eye within the last 6 months.
- •Any surgery in the study eye within the last 3 months prior to inclusion into the study.
- •History of an uncontrolled glaucoma in the study eye
- •active inflammation in the study eye or the acular adnexa
- •Subfoveal fibrosis in the study eye
- •Inability to comply with the study protocol
- •Major general surgery one month prior to inclusion into the study
- •Known allergy to humanized antibodies
- •Pregnancy or insufficient contraception
- •History of serious cardio-vascular problems or stroke 6 months prior to inclusion into the study
研究者
相似试验
已完成
2 期
Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)Type 2 Idiopathic Macular TelangiectasiaNCT00504400University Hospital, Bonn10
进行中（未招募）
1 期
Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) TrialEUCTR2017-003243-37-GBMUST Coordinating Centre, John Hopkins Bloomberg School of Public Health240
进行中（未招募）
1 期
RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb study, with 12-month primary endpoint, assessing the efficacy and safety of Lucentis (Ranibizumab) in patients with visual impairment due to diabetic macular oedema.EUCTR2010-022616-39-GBovartis Pharmaceuticals UK Ltd
已完成
3 期
Intravitreal Bevacizumab for Idiopathic Macular TelangiectasiaRetinaTelangiectasisNCT00451763University of Sao Paulo31
已完成
1 期
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel FormationTelangiectasiaNCT00457145National Eye Institute (NEI)5